The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,352K data for 627K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

20 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Potent Small Agonists of Protease Activated Receptor 2.EBI
The University of Queensland
PAR2 Modulators Derived from GB88.EBI
The University of Queensland
Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity.EBI
The University of Queensland
Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists.EBI
Yonsei University
Inhibitors of the PAR-2 Signaling Pathway May Treat Pain and Inflammation.EBI
Therachem Research Medilab (India)
Toward drugs for protease-activated receptor 2 (PAR2).EBI
The University of Queensland
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.EBI
National Institute of Neuroscienc
Discovery of potent and selective small-molecule PAR-2 agonists.EBI
Acadia Pharmaceuticals
Potent agonists of the protease activated receptor 2 (PAR2).EBI
University of Arizona
Novel agonists and antagonists for human protease activated receptor 2.EBI
The University of Queensland
Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold.EBI
China Pharmaceutical University
Synthesis and initial pharmacology of dual-targeting ligands for putative complexes of integrin ?V?3 and PAR2.EBI
Marquette University
Discovery of Novel Nonpeptidic PAR2 Ligands.EBI
Friedrich-Alexander University Erlangen-N£Rnberg (Fau)
Design and Evaluation of Heterobivalent PAR1-PAR2 Ligands as Antagonists of Calcium Mobilization.EBI
Marquette University
Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.EBI
Shanghai Jiao Tong University
A refined agonist pharmacophore for protease activated receptor 2.EBI
University of Queensland
Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.EBI
Marquette University
Isoxazole-tethered diarylheptanoid analogs: Discovery of a new drug-like PAR2 antagonist.EBI
Advinus Therapeutics